MX379424B - Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis. - Google Patents

Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis.

Info

Publication number
MX379424B
MX379424B MX2015011878A MX2015011878A MX379424B MX 379424 B MX379424 B MX 379424B MX 2015011878 A MX2015011878 A MX 2015011878A MX 2015011878 A MX2015011878 A MX 2015011878A MX 379424 B MX379424 B MX 379424B
Authority
MX
Mexico
Prior art keywords
sub
fibrosis
alkenyl
alkyl
treatment
Prior art date
Application number
MX2015011878A
Other languages
English (en)
Spanish (es)
Other versions
MX2015011878A (es
Inventor
Boulos Zacharie
Brigitte Grouix
Lyne Gagnon
Pierre Laurin
Shaun Abbott
Original Assignee
Prometic Pharma Smt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma Smt Ltd filed Critical Prometic Pharma Smt Ltd
Publication of MX2015011878A publication Critical patent/MX2015011878A/es
Publication of MX379424B publication Critical patent/MX379424B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
MX2015011878A 2013-03-15 2014-03-14 Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis. MX379424B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798269P 2013-03-15 2013-03-15
PCT/CA2014/000236 WO2014138906A1 (en) 2013-03-15 2014-03-14 Substituted aromatic compounds and related method for the treatment of fibrosis

Publications (2)

Publication Number Publication Date
MX2015011878A MX2015011878A (es) 2016-06-07
MX379424B true MX379424B (es) 2025-03-11

Family

ID=51535669

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011878A MX379424B (es) 2013-03-15 2014-03-14 Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis.

Country Status (25)

Country Link
US (3) US10023518B2 (enExample)
EP (1) EP2970089B1 (enExample)
JP (1) JP6448562B2 (enExample)
KR (1) KR102196721B1 (enExample)
CN (2) CN110105200B (enExample)
AR (1) AR095429A1 (enExample)
AU (1) AU2014231648B2 (enExample)
BR (1) BR112015022008A2 (enExample)
CA (1) CA2905621C (enExample)
CL (1) CL2015002535A1 (enExample)
DK (1) DK2970089T3 (enExample)
EA (1) EA030651B1 (enExample)
ES (1) ES2741439T3 (enExample)
IL (1) IL241178B (enExample)
MX (1) MX379424B (enExample)
MY (1) MY180305A (enExample)
NZ (1) NZ712797A (enExample)
PH (1) PH12015502011B1 (enExample)
PL (1) PL2970089T3 (enExample)
PT (1) PT2970089T (enExample)
SG (1) SG11201507408XA (enExample)
TW (1) TWI689490B (enExample)
UY (1) UY35402A (enExample)
WO (1) WO2014138906A1 (enExample)
ZA (1) ZA201507061B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
AU2014207691B2 (en) 2013-01-15 2018-08-30 Incyte Holdings Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
ES2875336T3 (es) * 2014-10-10 2021-11-10 Liminal Biosciences Ltd Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
US20180228750A1 (en) * 2014-10-10 2018-08-16 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
UY36399A (es) 2014-11-12 2016-06-30 Prometic Biosciences Inc Compuestos aromáticos sustituidos y composiciones farmacéuticas para la autoreparación y regeneración del tejido
SG11201707555RA (en) * 2015-03-18 2017-10-30 Vectus Biosystems Ltd Compositions for the treatment of kidney and/or liver disease
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
JP7034914B2 (ja) * 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および/または線維性疾患の治療のための抗α-vインテグリン抗体
JP6718522B2 (ja) * 2016-05-19 2020-07-08 長弘生物科技股▲ふん▼有限公司 肺線維症の発症および/または治療の遅延のための医薬製剤
US20190328850A1 (en) 2016-12-15 2019-10-31 Talengen International Limited Method for preventing and treating lipid metabolism disorders and related diseases thereof
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR102126389B1 (ko) * 2018-09-14 2020-06-25 셀라이온바이오메드 주식회사 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물
EA202190890A1 (ru) 2018-10-11 2021-09-10 Басф Ас Получение замещенных ароматических соединений и их применение в фармацевтике
AU2021356346A1 (en) * 2020-10-06 2023-06-15 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183519A1 (en) * 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
EP2020849A2 (en) * 2006-05-26 2009-02-11 Auspex Pharmaceuticals Inc. Preparation and utility of substituted carboxylic acid compounds
CN105233294A (zh) * 2007-02-08 2016-01-13 爱密斯菲尔科技公司 苯烷基羧酸输送剂
PL2427417T3 (pl) * 2009-05-04 2014-03-31 Prometic Pharma Smt Ltd Sole kwasu 3-pentylofenylooctowego i ich farmaceutyczne zastosowania
PL2427416T3 (pl) * 2009-05-04 2016-09-30 Podstawione związki aromatyczne i ich zastosowania farmaceutyczne
AT509045B1 (de) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale

Also Published As

Publication number Publication date
PH12015502011B1 (en) 2020-12-04
KR20160051676A (ko) 2016-05-11
US20160039736A1 (en) 2016-02-11
ZA201507061B (en) 2017-03-26
US20200172462A1 (en) 2020-06-04
ES2741439T3 (es) 2020-02-11
EP2970089B1 (en) 2019-05-08
TW201441186A (zh) 2014-11-01
HK1220440A1 (en) 2017-05-05
JP6448562B2 (ja) 2019-01-09
TWI689490B (zh) 2020-04-01
WO2014138906A1 (en) 2014-09-18
AR095429A1 (es) 2015-10-14
CA2905621A1 (en) 2014-09-18
EP2970089A1 (en) 2016-01-20
EA201591775A1 (ru) 2016-05-31
US20180237374A1 (en) 2018-08-23
PT2970089T (pt) 2019-09-04
CN110105200B (zh) 2022-04-12
MX2015011878A (es) 2016-06-07
CN105189438A (zh) 2015-12-23
US11524930B2 (en) 2022-12-13
EA030651B1 (ru) 2018-09-28
US10550066B2 (en) 2020-02-04
CL2015002535A1 (es) 2016-03-28
NZ712797A (en) 2020-08-28
IL241178B (en) 2020-09-30
JP2016512202A (ja) 2016-04-25
AU2014231648B2 (en) 2018-02-08
CN110105200A (zh) 2019-08-09
IL241178A0 (en) 2015-11-30
SG11201507408XA (en) 2015-10-29
DK2970089T3 (da) 2019-08-05
MY180305A (en) 2020-11-27
AU2014231648A1 (en) 2015-10-22
KR102196721B1 (ko) 2020-12-30
PL2970089T3 (pl) 2020-01-31
UY35402A (es) 2014-10-31
BR112015022008A2 (pt) 2021-05-25
CA2905621C (en) 2021-06-29
US10023518B2 (en) 2018-07-17
PH12015502011A1 (en) 2016-01-11
EP2970089A4 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
MX379424B (es) Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis.
MX375261B (es) Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
PH12018500777A1 (en) Farnesoid x receptor modulators
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
WO2012174487A3 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2012015986A3 (en) Substituted dioxopiperidinyl phthalimide derivatives
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
MX2015012111A (es) Moduladores de ship1 y métodos relacionados con éstos.
FR2977486B1 (fr) Compositions cosmetiques sous la forme d'emulsions eau-dans-huile comprenant un derive d'acide jasmonique
HK1218537A1 (zh) 香豆素衍生物以及用於治疗过度增生性疾病的方法
WO2012131656A3 (en) Compounds for use as therapeutic agents affecting p53 expression and/or activity
WO2014130752A3 (en) Bicyclic compounds
PH12019500822B1 (en) Crystalline forms of eravacycline
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2013117503A3 (en) Pi3k inhibitors for treating fibrotic diseases
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof